PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (C.B.).\', \'Office of the Director, National Institutes of Health, Bethesda, Maryland (R.W.E., J.M.A., F.S.C.).\', \'Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (A.M.L., A.S.F.).\', \'Office of the Commissioner, Food and Drug Administration, Silver Spring, Maryland (J.W.).\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.7326/M21-3669
?:doi
?:hasPublicationType
?:journal
  • Annals of internal medicine
is ?:pmid of
?:pmid
?:pmid
  • 34724404
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 7.466
?:rankingScore_hIndex
  • 349
?:title
  • Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34724404>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34724404>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all